# Unicycive Therapeutics, Inc.: overview

UNCY · Nasdaq · CIK 1766140 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/uncy.md) · [Financials](/companies/uncy/financials.md) · [Filings](/companies/uncy/filings.md) · [Insiders](/companies/uncy/insiders.md)

Latest reported revenue: [$0](/filings/0001213900-25-025828.md) for Q4 FY2023, three months to 2023-12-31, from the 10-K filed Mar 31, 2025 (XBRL us-gaap:Revenues, accession 0001213900-25-025828).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.46)](/filings/0001213900-25-108600.md) | not reported | [(0.50)](/filings/0001213900-26-054708.md) | [(0.52)](/filings/0001213900-26-088013.md) | [(0.33)](/filings/0001213900-25-108600.md) | not reported | [(0.54)](/filings/0001213900-26-054708.md) | [(0.06)](/filings/0001213900-26-088013.md) |
| Free cash flow | $k | [(9,276) d](/filings/0001213900-25-108600.md) | [(6,570) d](/filings/0001213900-26-035903.md) | [(8,919)](/filings/0001213900-26-054708.md) | [(8,426) d](/filings/0001213900-26-088013.md) | [(5,964) d](/filings/0001213900-25-108600.md) | [(8,032) d](/filings/0001213900-26-035903.md) | [(6,249)](/filings/0001213900-26-054708.md) | [(7,605) d](/filings/0001213900-26-088013.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [1.0](/filings/0001213900-24-027202.md) | [0.7](/filings/0001213900-25-025828.md) | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [(1898.2%)](/filings/0001213900-24-027202.md) | [(3077.6%)](/filings/0001213900-25-025828.md) | not reported | not reported |
| Net margin | % | not reported | [(1898.8%)](/filings/0001213900-24-027202.md) | [(4525.0%)](/filings/0001213900-25-025828.md) | not reported | not reported |
| Diluted EPS | $ per share | [(0.86)](/filings/0001213900-23-024901.md) | [(1.20)](/filings/0001213900-24-027202.md) | [(1.28)](/filings/0001213900-25-025828.md) | [(5.65)](/filings/0001213900-26-035903.md) | [(1.67)](/filings/0001213900-26-035903.md) |
| Free cash flow | $m | [(5.8)](/filings/0001213900-23-024901.md) | [(15.7)](/filings/0001213900-24-027202.md) | [(18.3)](/filings/0001213900-25-025828.md) | [(28.6)](/filings/0001213900-26-035903.md) | [(31.3)](/filings/0001213900-26-035903.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/uncy/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $6.6m | 1,413,381 |  | Added +1,377,478 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $6.6m | 1,401,447 |  | Added +462,245 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $6.6m | 1,401,447 |  | Added +462,245 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.0m | 1,071,481 |  | Added +260,051 |
| [Octagon Capital Advisors LP](/funds/1839435.md) | 2026-06-30 | $4.7m | 1,000,000 |  | Unchanged |
| [DIADEMA PARTNERS LP](/funds/2026172.md) | 2026-06-30 | $3.7m | 792,600 | Call | New +792,600 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.6m | 564,019 |  | Added +360,275 |
| [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $2.6m | 550,000 |  | Reduced −1,239,916 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $2.6m | 547,862 |  | Added +392,924 |
| [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $2.2m | 473,563 |  | Unchanged |

## Recent filings

[All 305 filings](/companies/uncy/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-29 | 07:46 ET | [8-K](/filings/0001213900-26-104314.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-104314 |
| 2026-09-28 | 16:31 ET | [8-K](/filings/0001213900-26-104076.md) | 8.01 Other events | 0001213900-26-104076 |
| 2026-08-12 | 08:04 ET | [8-K](/filings/0001213900-26-088061.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-088061 |
| 2026-08-12 | 06:30 ET | [10-Q](/filings/0001213900-26-088013.md) | Quarterly report, period 2026-06-30 | 0001213900-26-088013 |
| 2026-07-02 | 10:30 ET | [8-K](/filings/0001213900-26-074678.md) | 8.01 Other events | 0001213900-26-074678 |
| 2026-06-22 | 06:05 ET | [8-K](/filings/0001213900-26-070316.md) | 5.07 Shareholder vote results | 0001213900-26-070316 |
| 2026-06-05 | 16:19 ET | [8-K](/filings/0001213900-26-065828.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-065828 |
| 2026-05-12 | 07:51 ET | [8-K](/filings/0001213900-26-054736.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-054736 |
| 2026-05-12 | 06:30 ET | [10-Q](/filings/0001213900-26-054708.md) | Quarterly report, period 2026-03-31 | 0001213900-26-054708 |
| 2026-04-30 | 07:00 ET | [DEF 14A](/filings/0001213900-26-049690.md) | Proxy statement, period 2026-06-19 | 0001213900-26-049690 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-035903.md), filed Mar 30, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1766140
- Tickers: UNCY
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:30 ET. No prices; not investment advice.